Janus Henderson Group
PETX

Janus Henderson Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Janus Henderson Group’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,801,381
Closed -$9.47M – 1410
2017
Q4 		$9.47M Hold
1,801,381
– – 0.01% 881
2017
Q3 		$11M Buy
1,801,381
+10,551
+0.6% +$66.8K 0.01% 848
2017
Q2 		$12.9M Buy
+1,790,830
New +$11M 0.01% 825

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Janus Henderson Group's PETX Position: Q1 2018 in Review

Janus Henderson Group sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 1,801,381 shares — an estimated $9.47M sold.

Janus Henderson Group first reported a position in PETX in Q2 2017 and held it in 3 quarters. The position peaked at $12.9M in Q2 2017. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

  • Janus Henderson Group reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Janus Henderson Group sold 1,801,381 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $9.47M.
  • Janus Henderson Group first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • Janus Henderson Group's Aratana Therapeutics, Inc. position peaked at $12.9M in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on Janus Henderson Group's 13F filing for Q1 2018, filed 14 May 2018.